Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis
Open accessThe DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Semaglutide, a glucagon-like peptide-1 receptor agonist, is a candidate for the treatment of metabolic dysfunction-associated steatohepatitis (MASH). METHODS: In this ongoing phase 3, multicenter, randomized, double-blind, placebo-controlled trial, we assigned 1197 patients with biopsy-defined MASH and fibrosis stage 2 or 3 in a 2:1 ratio to receive once-weekly subcutaneous semaglutide at a dose of 2.4 mg or placebo for 240 weeks. The results of a planned interim analysis conducted at week 72 involving the first 800 patients are reported here (part 1). The primary end points for part 1 were the resolution of steatohepatitis without worsening of liver fibrosis and reduction in liver fibrosis without worsening of steatohepatitis. RESULTS: Resolution of steatohepatitis without worsening of fibrosis occurred in 62.9% of the 534 patients in the semaglutide group and in 34.3% of the 266 patients in the placebo group (estimated difference, 28.7 percentage points; 95% confidence interval [CI], 21.1 to 36.2; P<0.001). A reduction in liver fibrosis without worsening of steatohepatitis was reported in 36.8% of the patients in the semaglutide group and in 22.4% of those in the placebo group (estimated difference, 14.4 percentage points; 95% CI, 7.5 to 21.3; P<0.001). Results for the three secondary outcomes that were included in the plan to adjust for multiple testing were as follows: combined resolution of steatohepatitis and reduction in liver fibrosis was reported in 32.7% of the patients in the semaglutide group and in 16.1% of those in the placebo group (estimated difference, 16.5 percentage points; 95% CI, 10.2 to 22.8; P<0.001). The mean change in body weight was -10.5% with semaglutide and -2.0% with placebo (estimated difference, -8.5 percentage points; 95% CI, -9.6 to -7.4; P<0.001). Mean changes in bodily pain scores did not differ significantly between the two groups. Gastrointestinal adverse events were more common in the semaglutide group. CONCLUSIONS: In patients with MASH and moderate or advanced liver fibrosis, once-weekly semaglutide at a dose of 2.4 mg improved liver histologic results. (Funded by Novo Nordisk; ClinicalTrials.gov number, NCT04822181.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“A recent study reported significant effects on the resolution of MASLD without worsening of fibrosis, but also significant improvements in fibrosis without worsening of MASLD after 72 weeks of treatment with semaglutide.84”
From GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (2026) · cites this paper as [84]
In the citing paper
“Part 1 of a phase III trial investigating semaglutide for the treatment of MASH demonstrated resolution of steatohepatitis with no worsening of fibrosis in 63% of the semaglutide group, compared with 34% in the placebo group (68).”
From Antiinflammatory actions of glucagon-like peptide-1–based therapies beyond metabolic benefits (2025) · cites this paper as [68]
In the citing paper
“In addition, 37% of the semaglutide group showed improvement in fibrosis without worsening of steatohepatitis, compared with 23% in the placebo group.”
From Antiinflammatory actions of glucagon-like peptide-1–based therapies beyond metabolic benefits (2025) · cites this paper as [68]
In the citing paper
“As for resmitirom, semaglutide is indicated for MASH patients with moderate to advanced liver fibrosis, but not liver cirrhosis (53).”
From Targeting macrophages in liver fibrosis (2026) · cites this paper as [53]
In the citing paper
“In the ESSENCE phase 3 trial, semaglutide showed a significant antifibrotic effect in patients with MASH and stage F2–F3 fibrosis (225).”
From Strategies to promote liver fibrosis amelioration with involvement of restorative macrophages (2026) · cites this paper as [225]
9 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791
Self-citationSemaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205
Mechanisms of NAFLD development and therapeutic strategies
Friedman, S. L., Neuschwander-Tetri, B. A., Rinella, M., & Sanyal, A. J. (2018) · Nature Medicine · doi:10.1038/s41591-018-0104-9 · Cited by 4,354
Self-citationSemaglutide and Cardiovascular Outcomes in Obesity without Diabetes
Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., Hardt-Lindberg, S., Hovingh, G. K., Kahn, S. E., Kushner, R. F., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2307563 · Cited by 3,236
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
Rinella, M. E., Lazarus, J. V., Ratziu, V., Francque, S. M., Sanyal, A. J., Kanwal, F., Romero, D., Abdelmalek, M. F., Anstee, Q. M., Arab, J. P., et al. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.06.003 · Cited by 3,100
Self-citationNon-alcoholic fatty liver disease
Powell, E. E., Wong, V. W.-S., & Rinella, M. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32511-3 · Cited by 2,789
Self-citationRinella, M. E., Neuschwander-Tetri, B. A., Siddiqui, M. S., Abdelmalek, M. F., Caldwell, S., Barb, D., Kleiner, D. E., & Loomba, R. (2023) · Hepatology · doi:10.1097/hep.0000000000000323 · Cited by 2,667
Self-citationA phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis
Harrison, S. A., Bedossa, P., Guy, C. D., Schattenberg, J. M., Loomba, R., Taub, R., Labriola, D., Moussa, S. E., Neff, G. W., Rinella, M. E., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2309000 · Cited by 2,084
Self-citationA Placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis
Newsome, P. N., Buchholtz, K., Cusi, K., Linder, M., Okanoue, T., Ratziu, V., Sanyal, A. J., Sejling, A.-S., & Harrison, S. A. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2028395 · Cited by 2,039
Self-citation
Cited by
Items 101–200 of 1,000
Proglucagon-derived peptides: human physiology and therapeutic potential
Gasbjerg, L. S., Nielsen, C. K., Suppli, M. P., Grøndahl, M. F. G., Holst, J. J., Knop, F. K., Jeppesen, P. B., & Lund, A. (2025) · Physiological Reviews · doi:10.1152/physrev.00057.2024 · Cited by 22
Resmetirom for MASH: A Comprehensive Review of a Novel Therapeutic Frontier
Tiwari, A., Sharma, A., Kumar, H., Gupta, V., Deshpande, V., Mupparaju, J. S., Mishra, T., Bharadwaj, H. R., Dahiya, D. S., & Jain, V. (2025) · Biomedicines · doi:10.3390/biomedicines13092079 · Cited by 23
“Taken together, semaglutide resulted in significant improvements in liver histology in MASH [56].”
Iruzubieta, P., de Vega, T., & Crespo, J. (2025) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(25)00226-2 · Cited by 20
Goodheart, R. H., & Ayonrinde, O. T. (2025) · Heart Lung and Circulation · doi:10.1016/j.hlc.2025.08.009 · Cited by 21
Tissue regeneration: Unraveling strategies for resolving pathological fibrosis
Li, J., Wang, S., Yuan, J., Mao, X., Wang, X., Zhang, L., Dong, Q., Chen, Z., Wang, Y., & Tang, N. (2025) · Cell stem cell · doi:10.1016/j.stem.2025.10.002 · Cited by 23
Incretin-Based Therapies Through the Decades: Molecular Innovations and Clinical Impact
Lee, A. A., Khotina, V. A., Kashirskikh, D. A., Voronko, O. E., Gasanov, V. A. O., & Vasiliev, A. V. (2025) · Medical Sciences · doi:10.3390/medsci13040269 · Cited by 26
Jamalinia, M., Saeian, S., Nikkhoo, N., Nazerian, A., & Lankarani, K. B. (2025) · Metabolism and Target Organ Damage · doi:10.20517/mtod.2025.131 · Cited by 20
The many pathways driving liver inflammation in MASH
Tilg, H., Adolph, T. E., Romeo, S., & Loomba, R. S. (2026) · Cell Metabolism · doi:10.1016/j.cmet.2026.02.018 · Cited by 20
Implementing sustainable liver health in Europe: a second EASL–Lancet Commission
Karlsen, T. H., Hutchinson, S. J., Zelber‐Sagi, S., Carrieri, P., Negro, F., Lim, A. G., Cecchini, M., Dirac, M. A., Murray, F., Engebretsen, E., et al. (2026) · The Lancet · doi:10.1016/s0140-6736(26)00138-8 · Cited by 21
Self-citationPharmacologic treatment of obesity in adults: Standards of care in overweight and obesity
C, K. A. C. M. V. R. L. J. K. A. G. A. A. A. B. B. (2025) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2025-005729 · Cited by 36
“Obesity-related diseases and conditions that benefit from this weight-loss magnitude include metabolic dysfunction–associated steatohepatitis with moderate- to-severe fibrosis, 7 46 heart failure with preserved ejection fraction, 47 48 and knee osteoarthritis.”
Giannakogeorgou, A., Roden, M., & Pafili, K. (2025) · HORMONES · doi:10.1007/s42000-025-00701-y · Cited by 24
Self-citationAllahwala, M. A., Marathe, C. S., Nelson, A. J., Psaltis, P. J., & Marathe, J. (2025) · Heart Lung and Circulation · doi:10.1016/j.hlc.2025.07.005 · Cited by 17
Weiskirchen, R., & Lonardo, A. (2025) · Medical Sciences · doi:10.3390/medsci13040265 · Cited by 22
“Table 2 [32–37] provides an at-glance chronology of the key pre-clinical discoveries, clinical trials and regulatory decisions that have shaped the journey of semaglutide from its early laboratory design to its current benchmark status in metabolic medicine.”
InfluentialGLP-1 agonists and exercise: the future of lifestyle prioritization
Codella, R., Senesi, P., & Luzi, L. (2025) · Frontiers in Clinical Diabetes and Healthcare · doi:10.3389/fcdhc.2025.1720794 · Cited by 16
Rabbani, N., & Thornalley, P. J. (2025) · Clinical Science · doi:10.1042/cs20257727 · Cited by 17
Targeting ferroptosis to halt MASLD and MASH
Wang, F. (2026) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2026.01.007 · Cited by 18
Liver regeneration: unraveling the molecular mechanisms and clinical application
Wang, N., Guo, M., Zhang, C., Jiang, R., Bi, J., Sun, J., & Liu, B. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-07412-3 · Cited by 19
Ajmera, V. H., Vuppalanchi, R., Khalili, M., Sheikh, M. Y., Risser, J. A., Klein, S., Tincopa, M. A., Madamba, E. V., Singh, S., Siddiqi, H., et al. (2026) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.70516 · Cited by 17
Pharmacologic Treatment of Obesity in Adults: Standards of Care in Overweight and Obesity
Gudzune, K. A., Apovian, C. M., Aroda, V. R., Aronne, L. J., Balapattabi, K., Bennett, A. K., ChallaSivaKanaka, S., ElSayed, N. A., Fitch, A., Fitzpatrick, S. L., et al. (2026) · Diabetes Obesity and Cardiometabolic CARE · doi:10.2337/doci25-0008 · Cited by 27
The evolving landscape of obesity pharmacotherapy
Petersen, J., Finan, B., Johansen, V. B. I., Müller, T. D., & Clemmensen, C. (2026) · Nature Reviews Drug Discovery · doi:10.1038/s41573-026-01427-1 · Cited by 19
Tirzepatide reduces alcohol drinking and relapse-like behaviours in rodents
Edvardsson, C. E., Adermark, L., Gottlieb, S., Alfreji, S., Emous, T. A., Gouda, Y., Thorsell, A., Vujičić, M., Aranäs, C., Benrick, A., et al. (2026) · EBioMedicine · doi:10.1016/j.ebiom.2025.106119 · Cited by 16
The Liver in Diabetes and Metabolic Syndrome
Mahmoud, M. C., & Abdelmalek, M. F. (2025) · Clinics in Liver Disease · doi:10.1016/j.cld.2025.04.003 · Cited by 14
GLP-1 receptor agonists in alcohol use disorder and alcohol-associated liver disease
Singal, A. K., & Leggio, L. (2025) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(25)00134-7 · Cited by 15
Heart–liver co-management in MASLD: from concept to clinical practice
Zhou, X., & Zheng, M. (2025) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-025-01144-x · Cited by 14
“• Semaglutide demonstrated efficacy across hepatic and cardiometabolic outcomes in metabolic dysfunction-associated steatotic liver disease (MASLD), providing pharmacological support for heart–liver co-management 1 .”
Barana, L., De Fano, M., Cavallo, M., Manco, M., Prete, D., Fanelli, C. G., Porcellati, F., & Pippi, R. (2025) · Nutrients · doi:10.3390/nu18010131 · Cited by 13
“…use in knee osteoarthritis (STEP-9 trial) [26], and demonstrated histological benefits in metabolic dysfunction-associated steatohepatitis (MASH) (ESSENCE trial) [27], leading to Food and Drug Administration (FDA) approval for the treatment of MASH with moderate-to-advanced fibrosis [28].”
Tornea, D. A., Goldiș, C., Isaic, A., Motofelea, A. C., Sima, A. C., Ciocârlie, T., Crintea, A., Diaconescu, R. G., Motofelea, N., & Goldiș, A. (2026) · Pharmaceutics · doi:10.3390/pharmaceutics18010086 · Cited by 13
“Eight studies [14,16,20,29–33] included patients with MASH, while four studies [15,25,26,31] included patients without type 2 diabetes.”
InfluentialGlucagon-like peptide-1 medicines and cancer
Yabut, J. M., & Drucker, D. J. (2026) · Nature Cancer · doi:10.1038/s43018-025-01110-1 · Cited by 15
Meyhöfer, S. M., Cariou, B., Cercato, C., Colhoun, H. M., Deanfield, J. E., Long, M. T., Jeppesen, O. K., Lincoff, A. M., Lingvay, I., Plutzky, J., et al. (2026) · Nature Medicine · doi:10.1038/s41591-026-04281-1 · Cited by 13
“Recently, results from the first 72-week interim analysis of 800 patients in ESSENCE showed that semaglutide 2.4 mg leads to significant resolution of MASH, improvement in liver fibrosis and improvements in cardiometabolic risk factors compared with placebo 13 .”
InfluentialSelf-citationAnker, S. D., Ji, L., Kindel, T., Coats, A. J. S., Ojji, D., Puente-Barragán, A., Rossing, P. R., Zieroth, S. R., Ahmad, S., Usman, S., et al. (2025) · Global Cardiology · doi:10.4081/cardio.2025.86 · Cited by 17
Bril, F., Bolla, P., Huynh, K., & Bobba, S. S. (2025) · Journal of the Endocrine Society · doi:10.1210/jendso/bvaf110 · Cited by 14
“While all GLP-1RA have shown improvement in hepatic steatosis, only tirzepatide (at 5, 10, and 15 mg weekly doses) and semaglutide 2.4 mg weekly have been shown to reduce liver fibrosis [40, 41].”
InfluentialCosta, E. G., Bitetto, D., Fornasiere, E., Fumolo, E., Ferrarese, A., & Toniutto, P. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14134619 · Cited by 14
“In addition, semaglutide [19] and tirzepatide [20], which are the GLP-1RAs more often used, have shown an important clinical benefit in reducing liver steatosis and/or fibrosis in patients with MASLD.”
Steatotic Liver Disease in Older Adults: Clinical Implications and Unmet Needs
Clayton‐Chubb, D., Kemp, W. W., Majeed, A., Lange, P. W., Fitzpatrick, J. A., Vaz, K., Lubel, J. S., Hodge, A. D., Ryan, J. L., McNeil, J. J., et al. (2025) · Nutrients · doi:10.3390/nu17132189 · Cited by 14
“Recently, the final data from the ESSENCE randomised controlled trial of 2.4 mg semaglutide versus placebo in MASH showed marked improvements in both steatohepatitis and liver fibrosis compared with placebo [252].”
InfluentialYounossi, Z. M., Wong, V. W., Tsochatzis, E. A., Castéra, L., Betel, M., Henry, L. L., & Zelber‐Sagi, S. (2025) · Liver International · doi:10.1111/liv.70311 · Cited by 14
“The approval of resmetirom and semaglutide for MASH, and the use of GLP-1 receptor agonists for weight loss and glycae-mic control, represent significant milestones in MASLD/MASH treatment [84, 86].”
InfluentialNitze, L. M., Ratziu, V., Sanyal, A. J., Wong, V. W., Balendran, C. A., Fleckner, J., Kjær, M. S., Krarup, N., & Anstee, Q. M. (2025) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.70376 · Cited by 13
Self-citationNeff, G. W. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70148 · Cited by 13
The transition from NAFLD to MASLD: implications for Diagnosis, Prognosis, and Clinical Management
Acierno, C., Nevola, R., Barletta, F., Zielińska, K., Rinaldi, L., Sasso, F. C., Conte, C., Adinolfi, L. E., & Caturano, A. (2025) · Exploration of Medicine · doi:10.37349/emed.2025.1001365 · Cited by 14
Sun, J.-R., Sun, X.-N., Lu, B.-J., & Deng, B. (2025) · World Journal of Gastroenterology · doi:10.3748/wjg.v31.i46.111176 · Cited by 14
Huang, H.-T., Hewitt, M. J., Li, W., & Alazawi, W. (2025) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2025.101557 · Cited by 21
“This is particularly relevant for real-world efficacy and pharmacovigilance as resmetirom 16 and semaglutide 17 — and soon other drugs — will be used specifically for MASH and fibrosis.”
SOUZA, M. M. X. D., Al‐Sharif, L., Antunes, V., Wong, S. Y., Huang, D. Q., & Loomba, R. S. (2026) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.70565 · Cited by 13
APASL clinical practice guidelines on the management of chronic hepatitis B infection: a 2026 update
You, H., Maiwall, R., Chen, J., Ahn, S. H., Dokmeci, K., 窦晓光, El-Sayed, M., Fan, J.-G., Gani, R., Gao, Z., et al. (2026) · Hepatology International · doi:10.1007/s12072-026-11108-1 · Cited by 21
“…of metabolic dysfunction-associated steatohepatitis (MASH), mean baseline ALT typically ranges from 40 to 70 U/L and rarely exceeds 200 U/L [62–65], whereas CHB patients in the “indeterminate phase” exhibit higher fibrosis stages and greater HCC risk than those with low viraemic activity [66].”
Semaglutide in MASLD Patients: Improved Survival and Liver Outcomes
Suki, M., Amer, J., Milgrom, Y., Massarwa, M., Hazou, W., Tiram, Y., Perzon, O., Sharif, Y., Sackran, J., Alon, R., et al. (2025) · Pharmaceuticals · doi:10.3390/ph18071075 · Cited by 12
“These findings are in line with published data showing fibrosis regression by semaglutide [33].”
Proteomic signatures reflect effects of semaglutide treatment for MASH
Schattenberg, J. M., Grønbæk, H., Kliers, I., Ladelund, S., Long, M. T., Nygård, S. B., Sanyal, A. J., & Davies, M. J. (2025) · JHEP Reports · doi:10.1016/j.jhepr.2025.101521 · Cited by 14
“20 The final area of investigation in this post hoc analysis was to provide supportive evidence for the utility of SomaSignal-derived data by assessing the concordance of SomaSignal-derived MASH components with equivalent biopsy-based MASH histology, simple liver-related biomarkers, and measures of…”
Self-citationMeasuring health-related quality of life and patient-reported outcomes in chronic liver disease
Younossi, Z. M., Stepanova, M., Schattenberg, J. M., & Henry, L. L. (2025) · Journal of Hepatology · doi:10.1016/j.jhep.2025.09.027 · Cited by 18
Murao, N., Seino, Y., Morikawa, R., Hidaka, S., Haraguchi, T., Tomatsu, E., Habara, M., Ohno, T., Yokoi, N., Harada, N., et al. (2025) · The Journal of Physiology · doi:10.1113/jp289067 · Cited by 11
“Pharmacological GLP-1 receptor agonists decrease hepatic steatosis in patients with metabolic dysfunction-associated steatohepatitis (MASH) (Sanyal et al., 2025) and fructose-fed rodents (Gao et al., 2020).”
Management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): Facts and Hopes
Adinolfi, L. E., Marrone, A., Izzi, A., & Craxì, A. (2025) · Journal of Clinical and Experimental Hepatology · doi:10.1016/j.jceh.2025.103411 · Cited by 11
Sanyal, A. J., Nakajima, A., Bugianesi, E., Sebastiani, G., Schattenberg, J. M., Adams, L. A., Noureddin, M., Yoneda, M., Bédossa, P., Younossi, Z. M., et al. (2025) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2025.12.001 · Cited by 18
Self-citationTargeting THR-β for MASLD Treatment: Current Progression and Emerging Prospects
Li, J., Chen, R., Zhang, J., He, J., Wang, Y., & Li, Y. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c03114 · Cited by 11
Moiz, A., Peters, T. M., Tsoukas, M. A., Yu, O. H. Y., Filion, K. B., & Eisenberg, M. J. (2026) · EClinicalMedicine · doi:10.1016/j.eclinm.2026.103991 · Cited by 15
“…outcomes, GLP-1 RAs show potential benefits across metabolic comorbidities, including metabolic dysfunction-associated steatotic liver disease, 17–19 obstructive sleep apnea, 20 knee osteoarthritis, 21 and polycystic ovary syndrome, 22–24 though durability of response requires longer-term data.”
Semaglutide: FDA approves weight loss jab to treat severe liver disease
Bowie, K. (2025) · BMJ · doi:10.1136/bmj.r1788 · Cited by 11
Das, S., Agarwal, K., Kapoor, N., Lakhani, O., & Gupta, A. D. (2025) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000935 · Cited by 10
MASLD in childhood as a multisystem health challenge beyond the liver
Esposito, M., Rimauro, I., Frattolillo, V., Forcina, G., Marzuillo, P., del Giudice, E. M., & Sessa, A. D. (2025) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2025.10.001 · Cited by 13
Borges, R. D. S., de Abreu, E. S., Berton, G. G., de Paula, L. H., Conegundes, A. F., Martins, J. M. B., Martins, M. A. B., Dahbour, A., Fernandes, M. V., & Abdelmalek, M. F. (2025) · JHEP Reports · doi:10.1016/j.jhepr.2025.101708 · Cited by 14
“Although the ESSENCE phase III trial, 29 which reported the highest MASH resolution rate (62.9%), contributed substantially to heterogeneity in the primary analysis (I 2 = 75.4%), this likely reflects differences in sample size and study design rather than inconsistency in the therapeutic effect of…”
InfluentialGenetic Predisposition to MASLD: Potential for Therapeutic Management
Karapanagiotidi, F., Boutari, C., & Sinakos, E. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27041933 · Cited by 10
“Semaglutide has shown promising results in a phase III trial, which included patients with biopsy-defined MASH and moderate/severe fibrosis, with both significant disease resolution and fibrosis improvement [40].”
Lessons from incretin-based therapy in MASH and obesity
Tilg, H., & Targher, G. (2025) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-025-01096-2 · Cited by 10
“Thus, the hepatic effectiveness of semaglutide on MASH and fibrosis, as observed by Sanyal et al. 2 , is presumably mainly driven by extrahepatic signals 1 .”
Youhanna, S., Taebnia, N., Liang, Y., Cheng, N., Wang, Y., Michel, M., & Lauschke, V. M. (2025) · Advanced Biology · doi:10.1002/adbi.202500337 · Cited by 9
Gholami, M., Balajam, N. Z., Rakhsha, S. S., Sajjadi‐Jazi, S. M., Shafiee, G., & Heshmat, R. (2025) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-025-01604-w · Cited by 9
Lee, B. K., Ghumman, U., Pedicone, L. D., Gómez-Aldana, A., & Lawitz, E. (2025) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2025.0337 · Cited by 11
Hamad, R. S., Kira, A. Y., Saber, S., Alharbi, M. S., Alsaykhan, H., Ahmed, S. S., Ahmed, H. H. T., Ahmed, A., Farrag, A. A. M., Eissa, H., et al. (2025) · International Immunopharmacology · doi:10.1016/j.intimp.2025.115480 · Cited by 9
Management of patients with type 2 diabetes and MASLD: An overview and joint statement
Chouik, Y., Canivet, C. M., Julla, J., Mouillot, T., Parlati, L., Rouland, A., Smati, S., Tramunt, B., Anty, R., Boursier, J., et al. (2025) · Diabetes & Metabolism · doi:10.1016/j.diabet.2025.101709 · Cited by 12
Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis: A Narrative Review
Zacharia, G. S., Gongati, S., Kharel, A., & Jacob, A. (2025) · Cureus · doi:10.7759/cureus.95632 · Cited by 12
Bianco, A., Bonfiglio, C., Franco, I., Bagnato, C. B., Verrelli, N., Stabile, D., & Shahini, E. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14217553 · Cited by 9
Sillassen, C. D. B., Petersen, J. J., Faltermeier, P., Yucel, D., Siddiqui, F., Andersen, R. K., Graever, L., Bjerg, J. L., Kamp, C. B., Grand, J., et al. (2025) · BMC Medicine · doi:10.1186/s12916-025-04486-0 · Cited by 10
“Non-serious adverse events were reported as outcomes in 45 trials [33–41, 43–46, 48–56, 58–67, 69–73, 75–79, 81, 82].”
Glucagon-like peptide-1 medicines in neurological and psychiatric disorders
Fang, S., Cui, F., & Drucker, D. J. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102511 · Cited by 12
Sonne, N., Roque, M., Zachariassen, L. F., Porsgaard, T., Pors, S. E., Cavalera, M., Jones, C., Osborn, O., Thorbek, D. D., Riis, M. L., et al. (2026) · EBioMedicine · doi:10.1016/j.ebiom.2026.106121 · Cited by 9
Tamaki, N., Kimura, T., Wakabayashi, S., Yamazaki, T., Iwadare, T., Tanaka, N., & Kurosaki, M. (2026) · Japanese Journal of Radiology · doi:10.1007/s11604-025-01930-2 · Cited by 11
Malandris, K., Charalampidis, K., Loomba, R. S., & Sinakos, E. (2026) · Current Diabetes Reports · doi:10.1007/s11892-026-01621-w · Cited by 12
Reinson, T., Bilson, J., Childs, C. E., Buchanan, R. M., Targher, G., & Byrne, C. D. (2026) · BMJ Medicine · doi:10.1136/bmjmed-2025-002038 · Cited by 12
Pilot study of epigenetic aging and treatment response to semaglutide in the SLIM LIVER study
Corley, M. J., Pang, A. P. S., Kitch, D. W., Kantor, A., Sattler, F. R., Belaunzarán-Zamudio, P. F., Brown, T. T., LANDAY, A. L., Lake, J. E., & Erlandson, K. M. (2026) · npj Aging · doi:10.1038/s41514-026-00383-9 · Cited by 13
“For example, ,weight,andglycemicindiceswithweekly 2.4mgdosingover48to72weeks 1,3,6 .”
Relevance of lipid droplets in metabolic dysfunction-associated steatotic liver disease
Weiskirchen, R., & Lonardo, A. (2026) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2026.2671694 · Cited by 9
Akuta, N., Kogiso, T., Ikejima, K., Otsuka, M., Kawaguchi, T., Kawanaka, M., Takahashi, H., Tamaki, N., Nakagawa, H., 疋田隼人, et al. (2026) · Journal of Gastroenterology · doi:10.1007/s00535-026-02408-2 · Cited by 10
Dobbie, L. J., Tolvanen, L., Alves, D., Baker, J. L., Bez, N. S., Birney, S., Bogl, L. H., Brown, A., Bullo, M., Clare, K., et al. (2026) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(26)00122-1 · Cited by 8
Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs): A Pan-Steatotic Liver Disease Treatment?
Chrysavgis, L., Mourelatou, N. G., & Cholongitas, Ε. (2025) · Biomedicines · doi:10.3390/biomedicines13071516 · Cited by 10
“In the phase 3 ESSENCE RCT, which included MASH patients with fibrosis stage F2/F3, semaglutide significantly improved histological activity, fibrosis markers, and cardiometabolic features after 72 weeks of treatment in comparison to placebo [81].”
Fiorucci, S., & Urbani, G. (2025) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2025.2546812 · Cited by 10
Nutrients as epigenetic modulators in metabolic dysfunction-associated steatotic liver disease
Rodríguez, S., Dahlem, M. L. F., Rossoni, C., Marroni, N. P., Marroni, C. A., & Fernandes, S. A. (2025) · World Journal of Hepatology · doi:10.4254/wjh.v17.i8.108182 · Cited by 8
Abaalkhail, F. A., Sanai, F. M., Alswat, K., Alzanbagi, A., Al-Jedai, A. H., Alshehri, A., Alfadda, A. A., Alghamdi, H., Almadi, M. A., AlEissa, M., et al. (2025) · Saudi Journal of Gastroenterology · doi:10.4103/sjg.sjg_199_25 · Cited by 12
Obesity Medication Treatment Perspectives Among People with Overweight or Obesity
Ostrominski, J. W., Chhibber, A., Kuti, E. L., Clark, B. J., & Donato, B. M. K. (2025) · Patient Preference and Adherence · doi:10.2147/ppa.s555622 · Cited by 8
Li, M., Hu, J., Chin, Y. H., Chew, H. S. J., & Wang, W. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1681965 · Cited by 9
“In the semaglutide treatment group (40), the incidence of serious SAEs was 13.4%.”
InfluentialWade, F. G., Lentine, K. L., Turk, D., Kirbach, K., Knobloch, T., Schnitzler, M. A., Qureshi, K., Syn, W., & Fleetwood, V. A. (2025) · Clinical Transplantation · doi:10.1111/ctr.70344 · Cited by 9
Immunometabolic integration in therapeutic strategies for managing MASLD
González-Serrano, S., Onoiu, A.-I., Camps, J., & Joven, J. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1693753 · Cited by 8
Holleboom, A. G., Francque, S., Cusi, K. J., & Caussy, C. (2025) · Metabolism Open · doi:10.1016/j.metop.2025.100424 · Cited by 11
Byun, S., Sotzen, M. R., Knappenberger, M. A., Bento, M. T., Asker, M., Olekanma, D. I., & Skibicka, K. P. (2025) · Comprehensive physiology · doi:10.1002/cph4.70083 · Cited by 8
New Treatment Options for MASLD Patients with Type 2 Diabetes
Mega, A., Turri, C., Marzi, L., Dauriz, M., Sacco, R., Floreani, A., & Stasi, C. (2026) · Life · doi:10.3390/life16020254 · Cited by 12
“The most recent phase 3 study by Sanyal et al. [105] was a multicenter, randomized, double-blind, placebo-controlled trial involving 1197 patients with biopsy-confirmed MASH and stage 2 or 3 fibrosis.”
SOUZA, M. M. X. D., Amaral, M. J. M., Moura, F. S., & Lima, L. C. V. (2026) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.70312 · Cited by 9
Koufakis, T., Kokkinos, A. D., & le Roux, C. W. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70723 · Cited by 9
Liu, M., Ma, Y., Cheang, W. S., Su, Z., & Xu, S. (2026) · Molecular Therapy · doi:10.1016/j.ymthe.2026.04.011 · Cited by 11
Quercetin in metabolic diseases: mechanisms, therapeutics, and multidimensional frontiers
Song, Q., Liu, L., Yang, Q., Pan, M., & Zhang, Y. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1800322 · Cited by 11
Aroda, V. R., Buzzetti, R., Dalskov, S., Jain, A. B., Larsen, J. S., Mathieu, C., Pratley, R. E., Videmark, A. N., Watt, T., & Buse, J. B. (2026) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(26)00126-9 · Cited by 10
Alkuwaiti, M. A., Al-Harbi, F. A., Alsaif, A. K., AlSughayyir, Z. M., Alsaud, R. S., Aljabr, M. N., Alanazi, A. K., Alosaily, A. A., Abdulqader, A. K. A., Almusabeh, H. A., et al. (2026) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.70589 · Cited by 8
Exploring hepatic stellate cell-driven fibrosis: therapeutic advances and future perspectives
Singh, A., Akhtar, A., & Shukla, P. (2025) · ADMET & DMPK · doi:10.5599/admet.2874 · Cited by 10
Future potential therapeutics to treat MASH
Mahajan, S., Malladi, N., & Banerjee, S. K. (2025) · Drug Discovery Today · doi:10.1016/j.drudis.2025.104451 · Cited by 10
Treatment Landscape of Metabolic-Dysfunction-Associated Steatotic Liver Disease
Patel, P. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14176060 · Cited by 7
“Semaglutide is part of an ongoing phase 3 clinical (ESSENCE) trial where its benefits on reducing biopsy proven steatohepatitis and liver fibrosis stage 2 or 3 is being studied [15].”
InfluentialWei, W., Lin, C., Luo, S., Huang, J., Hu, R.-T., Li, J., Ma, H., Wei, J.-Z., Wang, C., Lim, C.-S.-Y., et al. (2025) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2025.152703 · Cited by 7
Ndaa, M., Pandya, P., Swensson, J., Samala, N. R., Ajaz, S., Joshi, D., Ayoub, W. S., & Akisik, F. M. (2025) · Endocrine Practice · doi:10.1016/j.eprac.2025.09.205 · Cited by 12
Banerjee, M., Pal, R., & Pal, S. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70187 · Cited by 9
“…non-invasive markers or broader drug classes, 8,9 a comprehensive synthesis comparing the relative efficacy of anti-diabetic agents on liver fibrosis improvement, especially considering the dose stratification of incretin-based therapies and the recently published data, 4,7 remains unexplored.”
Fu, C., Deng, L., Zhu, X., Wang, B., Hu, B., Xue, H., Zeng, Q., & Zhang, Y. (2025) · Current Issues in Molecular Biology · doi:10.3390/cimb47100846 · Cited by 7
“Lifestyle modification remains the mainstay of management [9]; however, long-term adherence is notoriously difficult.”
Austrian multisociety consensus on metabolic dysfunction-associated steatotic liver disease
Mandorfer, M., Semmler, G., Aigner, E. S., Bräuer, A., Brix, J. M., Clodi, M., Datz, C., Effenberger, M., Felsenreich, D. M., Ludvik, B. H., et al. (2025) · Wiener klinische Wochenschrift · doi:10.1007/s00508-025-02617-4 · Cited by 8
“Specifically, the large phase 3 study on high-dose (2.4mg) semaglutide demonstrated improvement of MASH and fibrosis [61].”
Self-citationGenetic Assessment and Clinical Correlates in Severe Hypertriglyceridemia: A Systematic Review
Luca, C. D., Ciciola, P., D’Errico, G., Taranto, M. D. D., Fortunato, G., Gross, C., Garn, J., Iannuzzo, G., Minno, M. N. D. D., & Calcaterra, I. L. (2025) · Genes · doi:10.3390/genes16111377 · Cited by 9
“Recent therapeutic advances, including antisense oligonucleotides targeting APOC3 (volanesorsen, olezarsen), inhibitors of ANGPTL3 [29,30], and metabolic drugs such as GLP-1 [31–33] receptor agonists have opened new perspectives for the precision management of SHTG.”
Peng, Q., Hao, L., Li, S., Yu, F., Li, N., & Hu, X. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1640873 · Cited by 9
Choi, J., Kamath, T., Nguyen, V. H., Przybyszewski, E. M., Song, J., Carroll, A., Michta, M., Almazan, E., Simon, T. G., & Chung, R. T. (2025) · Liver International · doi:10.1111/liv.70447 · Cited by 9
Liver disease in people living with HIV infection: a changing landscape
Lee, F., & Bansal, M. B. (2025) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-025-01149-6 · Cited by 8
Metadata
- Authors
- Sanyal, A. J., Newsome, P. N., Kliers, I., Østergaard, L. H., Long, M. T., Kjær, M. S., Cali, A. M. G., Bugianesi, E., Rinella, M. E., Roden, M., & Ratziu, V.
- Affiliations
- Virginia Commonwealth University (US)
- King's College London (GB)
- Novo Nordisk (Denmark) (DK)
- University of Turin (IT)
- University of Chicago (US)
- Düsseldorf University Hospital (DE)
- Inserm (FR)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2025-06-05
- Volume
- 392
- Issue
- 21
- Pages
- 2089-2099
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4409963211
- Cited by
- 1,115
- References
- 39
- Citations by year
- 2026: 813 · 2025: 302
- FWCI
- 767.51
- Type
- journal article
- Language
- en
- Open access
- green
- hdl.handle.net
- Licence
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- University of Birmingham Research Portal (University of Birmingham) (publishedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion, other-oa)
- UWA Profiles and Research Repository (UWA) (submittedVersion)
- Scopus (Elsevier) (submittedVersion)
- Funders
- Novo Nordisk A/S
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- semaglutide, nonalcoholic steatohepatitis, GLP-1 receptor agonists, liver fibrosis, weight loss, body mass index, non-alcoholic fatty liver disease, fibrosis regression, interim analysis, multiple testing correction, non-invasive fibrosis markers
- MeSH terms
- Glucagon-Like Peptide-1 Receptor Agonists, Semaglutide, Adult, Aged, Biopsy, Double-Blind Method, Drug Administration Schedule, Female, Follow-Up Studies, Humans, Injections, Subcutaneous, Liver, Liver Cirrhosis, Male, Middle Aged, Severity of Illness Index, Treatment Outcome, Glucagon-Like Peptide 1, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.